Newron Reports Success in Evenamide Schizophrenia Study

Newron Pharmaceuticals S.p.A. disclosed successful top-line outcomes from its Phase II/III study 008A. This study tested evenamide, targeting patients with treatment-resistant schizophrenia. The primary endpoint, alongside a key secondary endpoint, was achieved, showing significant improvement in patient symptoms as measured by medical scales.

The study, spanning Europe, Asia, and Latin America across 45 centers, involved 291 schizophrenia sufferers undergoing treatment with a second-generation antipsychotic. Patients treated with evenamide noted substantial improvements without significant safety concerns. The drug’s tolerability was highlighted by the high completion rate of the study participants.

Evenamide operates through glutamatergic inhibition, representing a novel approach for patients unresponsive to existing antipsychotics. The results underscore its potential as a pioneering treatment, expanding therapeutic options in schizophrenia management.